S-Triazine Derivatives Targeting Vimentin for Broad-Spectrum Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases involving vimentin, such as cancer and pathogen infections, are limited in their ability to target vimentin's role in cellular processes like endocytosis, exocytosis, and endosomal trafficking, and in regulating T cell function.
Innovation Solution
Development of s-triazine derivatives that bind to vimentin, altering its spatial distribution and mobility, thereby inhibiting cell endocytosis, endosomal trafficking, and exosomal release, as well as activating regulatory T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct pathogen-fighting drugs are used, then effectiveness against specific pathogens is improved, but effectiveness against mutated pathogens or different pathogens deteriorates
Solution Approach 1:
The patent applies universality by developing host-directed drugs that target conserved cellular processes (endocytosis, endosomal trafficking, exosomal release) used by multiple pathogens and cancer cells. The compounds interfere with these universal cellular mechanisms, achieving broad-spectrum anti-pathogenic effects and anti-cancer activity simultaneously, rather than targeting specific pathogen structures.
Solution Approach 2:
The patent uses vimentin as an intermediary target. Vimentin is a host cell protein that serves as a mediator for pathogen infection and cancer progression. By targeting vimentin's role in cellular processes, the drugs indirectly affect multiple pathogens and cancer types, resolving the contradiction between specificity and versatility.
2Adaptability or versatility
If host-directed drugs targeting cellular processes are used, then broad-spectrum anti-pathogenic effects are improved, but specificity against particular infection mechanisms deteriorates
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula A with defined R1-R10 groups) that selectively interact with vimentin in specific cellular contexts. The structural variations in the compound series allow differentiation of effects based on cellular location and function, maintaining specificity while achieving broad spectrum activity.
Solution Approach 2:
The patent uses parameter changes by systematically varying molecular parameters (substituents R1-R10, Z, X groups) to optimize compound properties. This allows fine-tuning of binding affinity, cellular penetration, and selectivity for different vimentin functions, maintaining reliability across multiple applications while achieving broad spectrum effects.
3Reliability
If vimentin-targeting compounds are developed, then therapeutic effect against cancer and pathogens is improved, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex vimentin-targeting compound into modular components (Formula A framework with interchangeable R1-R10 groups, Z, and X moieties). This modular design allows independent optimization of each segment for specific functions (binding, penetration, efficacy) while simplifying the overall development process through systematic combination of standardized units.
Data Source
AI summary
Provided in the present invention is a compound for treating or preventing vimentin-mediated diseases. The compound of the present invention is a s-triazine derivative, as shown in the following formula A, or a pharmaceutically acceptable carrier, prodrug, enantiomer, diastereomer, tautomer or solvate thereof, wherein R1, R2 and Z are as defined herein. The present invention further comprises the corresponding pharmaceutical use, and a method for treating and preventing diseases.